Diagnosis and Treatment > Signs and Symptoms
Search for other papers by Carmina Teresa Fuss in
Google Scholar
PubMed
Search for other papers by Stephanie Burger-Stritt in
Google Scholar
PubMed
Search for other papers by Silke Horn in
Google Scholar
PubMed
Search for other papers by Ann-Cathrin Koschker in
Google Scholar
PubMed
Search for other papers by Kathrin Frey in
Google Scholar
PubMed
Search for other papers by Almuth Meyer in
Google Scholar
PubMed
Search for other papers by Stefanie Hahner in
Google Scholar
PubMed
Summary
Standard treatment of hypoparathyroidism consists of supplementation of calcium and vitamin D analogues, which does not fully restore calcium homeostasis. In some patients, hypoparathyroidism is refractory to standard treatment with persistent low serum calcium levels and associated clinical complications. Here, we report on three patients (58-year-old male, 52-year-old female, and 48-year-old female) suffering from severe treatment-refractory postsurgical hypoparathyroidism. Two patients had persistent hypocalcemia despite oral treatment with up to 4 µg calcitriol and up to 4 g calcium per day necessitating additional i.v. administration of calcium gluconate 2–3 times per week, whereas the third patient presented with high frequencies of hypocalcemic and treatment-associated hypercalcemic episodes. S.c. administration of rhPTH (1–34) twice daily (40 µg/day) or rhPTH (1–84) (100 µg/day) only temporarily increased serum calcium levels but did not lead to long-term stabilization. In all three cases, treatment with rhPTH (1–34) as continuous s.c. infusion via insulin pump was initiated. Normalization of serum calcium and serum phosphate levels was observed within 1 week at daily 1–34 parathyroid hormone doses of 15 µg to 29.4 µg. Oral vitamin D and calcium treatment could be stopped or reduced and regular i.v. calcium administration was no more necessary. Ongoing efficacy of this treatment has been documented for up to 7 years so far. Therefore, we conclude that hypoparathyroidism that is refractory to both conventional treatment and s.c. parathyroid hormone (single or twice daily) may be successfully treated with continuous parathyroid hormone administration via insulin pump.
Learning points:
-
Standard treatment of hypoparathyroidism still consists of administration of calcium and active vitamin D.
-
Very few patients with hypoparathyroidism also do not respond sufficiently to standard treatment or administration of s.c. parathyroid hormone once or twice daily.
-
In those cases, continuous s.c. administration of parathyroid hormone via insulin pump may represent a successful treatment alternative.
Search for other papers by Annika Sjoeholm in
Google Scholar
PubMed
Search for other papers by Cassandra Li in
Google Scholar
PubMed
Search for other papers by Chaey Leem in
Google Scholar
PubMed
Search for other papers by Aiden Lee in
Google Scholar
PubMed
Search for other papers by Maria P Stack in
Google Scholar
PubMed
Search for other papers by Paul L Hofman in
Google Scholar
PubMed
Paediatric Endocrinology, Southern District Health Board, Dunedin, New Zealand
Search for other papers by Benjamin J Wheeler in
Google Scholar
PubMed
Summary
Phaeochromocytomas are a rare clinical entity, with dual hormone-secreting lesions particularly uncommon, seen in <1%. ACTH is the most common hormone co-produced, and is potentially lethal if not diagnosed. We present the case of a previously well 10-year-old boy, who presented acutely with a hypertensive crisis and was found to have a unilateral, non-syndromic phaeochromocytoma. Medical stabilization of his hypertension was challenging, and took 3 weeks to achieve, before proceeding to unilateral adrenalectomy. Post-operatively the child experienced severe fatigue and was subsequently confirmed to have adrenal insufficiency. He improved markedly with hydrocortisone replacement therapy, which is ongoing 6 months post-operatively. In retrospect this likely represents unrecognized, sub-clinical ACTH-dependent Cushing's syndrome secondary to an ACTH/or precursor dual-hormone secreting phaeochromocytoma. At follow-up, his hypertension had resolved, there was no biochemical evidence of recurrence of the phaeochromocytoma, and genetic analysis was indicative of a sporadic lesion.
Learning points
-
Dual hormone secreting phaeochromocytomas with ACTH/or a precursor may cause secondary adrenal insufficiency following surgical removal.
-
The concurrent features of Cushing's syndrome can be mild and easily overlooked presenting diagnostic and management pitfalls.
-
As concomitant syndromes of hormone excess are rare in phaeochromocytomas; the diagnosis requires a high index of suspicion.
-
Serial/diurnal cortisol levels, ACTH measurement +/− low dose dexamethasone suppression (when clinically stable, appropriate adrenergic blockade in place, and well supervised), can all be considered as needed.
